Home › Calculator › UCBJY Dividend Calculator 2026
UCBJY Dividend DRIP Calculator 2026
0.58% YieldHealthcareUCB S.A. · OTC
Price: $146.13 · Annual div: $0.85/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When UCBJY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your UCBJY snowball 📈
$10,000 in UCBJY → $260.8K in 10 years · $9.99/month
About UCB S.A. (UCBJY) — Dividend Analysis 2026
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.
Compare UCBJY with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full UCBJY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open UCBJY position with:
🌍 UCBJY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold UCBJY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.58% | -2.22% | $58 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.49% | -2.31% | $49 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.46% | -2.34% | $46 / yr |
| 🇬🇧 UK ISA | 0% | 0.58% | -2.22% | $58 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.53% | -2.27% | $53 / yr |
| 🇨🇦 TFSA | 0% | 0.58% | -2.22% | $58 / yr |
| 🇨🇦 CA Taxable | 25% | 0.43% | -2.36% | $44 / yr |
| 🇦🇺 Super (pension) | 15% | 0.49% | -2.31% | $49 / yr |
| 🇦🇺 AU Taxable | 30% | 0.41% | -2.39% | $41 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.43% | -2.37% | $43 / yr |
| 🇫🇷 FR Taxable | 30% | 0.41% | -2.39% | $41 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 UCBJY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.85/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 UCBJY Dividend Payment Schedule
UCBJY pays quarterly — 4 times per year. Next ex-div: TBD.
📊 UCBJY vs Healthcare Benchmarks
How UCBJY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for UCBJY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ UCBJY Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the UCBJY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
UCB S.A. (UCBJY) is currently trading at $146.13, 6% below its 52-week high. The current dividend yield is 0.58% based on an annual payout of $0.85 per share.
UCBJY (UCB S.A.) — 0.58% Dividend Yield Analysis
UCB S.A. (UCBJY) is a healthcare stock currently trading at $146.13 with a dividend yield of 0.58%. The company pays an annual dividend of $0.85 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, UCBJY has grown its dividend at a compound annual rate of 7.3%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.